• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cardinal Health slides on missed Q3 EPS projections, supply chain-related headwinds

Cardinal Health slides on missed Q3 EPS projections, supply chain-related headwinds

May 5, 2022 By Sean Whooley

Cardinal HealthCardinal Health (NYSE:CAH) shares took a hit today on third-quarter results that missed the consensus earnings forecast.

CAH shares were down 5.3% at $57.30 per share in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down 3.1%. Today, the Dow Jones Industrial Average was down more than 3%, more than 1,100 points, as investors reevaluated the economic effects of the Federal Reserve’s plans to combat inflation.

The Dublin, Ohio-based company posted losses of $97 million, or $5.05 per share, on sales of $44.8 billion for the three months ended March 31, 2022, for a bottom-line slide into the red on sales growth of 14%.

Adjusted to exclude one-time items, earnings per share were $1.45, 7¢ behind Wall Street, where analysts were looking for sales of $43.2 billion.

Cardinal Health’s medical segment brought in 7% less revenues than the same quarter last year, while the segment’s profit dipped by 66% year over year. The company attributed its losses in the quarter in large part to a non-cash, pre-tax goodwill impairment of $474 million in its medical segment.

“While we’re taking action to drive performance across all our businesses, particularly the medical segment, our third quarter results reflect continued inflationary impacts and global supply chain constraints,” Cardinal Health CEO Mike Kaufmann said in a news release. “We have updated our outlook for medical to reflect the challenging environment, and reiterated our outlook for the pharmaceutical segment in fiscal year 2022. Going forward, we remain confident in our ability to drive sustainable, long-term growth.”

Cardinal Health updated its 2022 adjusted EPS guidance to a range of $5.15 to $5.25, keeping the low end the same while decreasing the high end by 25¢.

The company also updated expectations for its medical segment, with projections of a 45% to 55% decline in profits. The company had previously expected a 30%-45% decline. The medical outlook includes a year-over-year net incremental headwind of nearly $300 million due to inflationary and global supply chain constraint impacts.

Filed Under: Business/Financial News, Contract Manufacturing, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Cardinal Health

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy